2) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2002 ; 288 ; 2981-2997.
3) Julius S, Kjeldsen SE, Weber M, et al Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial. Lancet 2004 ; 363 : 2022-2031.
4) Dahlöf B, Sever PS, Poulter NR, et al : Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) ; a multicentre randomised controlled trial. Lancet 2005 ; 366 ; 895-906.
5) Jamerson K, Weber MA, Bakris GL, et al : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 ; 359 : 2417-2428.